Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma - Goyal, L; Saha, S K; Liu, L Y (Cancer Discov, 2017)
, et al.